Nivolumab versus Docetaxel in Advanced Nonsquamous Non–Small-Cell Lung Cancer
2015 · New England Journal of Medicine · 9,325 citations
https://doi.org/10.1056/nejmoa1507643
C
Charles M. Rudin
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
1.7K
Papers
86.3K
Citations
132
h-index
447
i10-index
Charles M. Rudin is an academic researcher from Memorial Sloan Kettering Cancer Center. The author has contributed to research in topics: Lung Cancer Research Studies & Lung Cancer Treatments and Mutations & Neuroendocrine Tumor Research Advances. The author has an h-index of 132, co-authored 1428 publications.
ORCID: 0000-0001-5204-3465Papers by this author
worksTumor mutational load predicts survival after immunotherapy across multiple cancer types
2019 · Nature Genetics · 4,300 citations
https://doi.org/10.1038/s41588-018-0312-8
Efficacy and Safety of Vismodegib in Advanced Basal-Cell Carcinoma
2012 · New England Journal of Medicine · 1,419 citations
https://doi.org/10.1056/nejmoa1113713
Small-cell lung cancer
2021 · Nature Reviews Disease Primers · 1,417 citations
https://doi.org/10.1038/s41572-020-00235-0
Molecular Determinants of Response to Anti–Programmed Cell Death (PD)-1 and Anti–Programmed Death-Ligand 1 (PD-L1) Blockade in Patients With Non–Small-Cell Lung Cancer Profiled With Targeted Next-Generation Sequencing
2018 · Journal of Clinical Oncology · 1,386 citations
https://doi.org/10.1200/jco.2017.75.3384
Genomic Features of Response to Combination Immunotherapy in Patients with Advanced Non-Small-Cell Lung Cancer
2018 · Cancer Cell · 1,159 citations
https://doi.org/10.1016/j.ccell.2018.03.018
Research topics
topicsChat about Author
Papers
Chat
Click to start Chat